Trial · NCT04542304
Efficacy of Diuretics in Kidney Disease
NCT04542304, Phase 2, Terminated, Stanford University; results first posted 2025-06-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Diuretics in Kidney Disease. Trials, record NCT04542304. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04542304
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Diuretics in Kidney Disease
- NCT number
- NCT04542304
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease
- Interventions
- Metolazone, Placebo
- First posted
- 2020-09-09
- Last updated
- 2025-06-05
- Results first posted
- 2025-06-05
- Limitations and caveats
- Early termination led to a small number of participants analyzed.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Urine Output | Change from baseline urine output at 1 week for each study arm | Average volume of urine produced in 24 hours. |
| Secondary | Kidney Clearance of Uremic Solutes | Kidney clearance of uremic solutes at 1 week for each study arm | Kidney clearance of uremic solutes in ml/min. |
| Secondary | Change in Quality of Life Questionnaire Score | Change from baseline quality of life score at 1 week for each study arm | Kidney Disease Quality of Life 36 Questionnaire (KDQOL36) |
| Secondary | Plasma Urea | Week 1 | |
| Secondary | Blood Pressure | Week 1 | |
| Secondary | Weight Change | Baseline, Week 1 |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Urine Output | Change from baseline urine output at 1 week for each study arm | mL/day | MEAN | |
| SECONDARY | Kidney Clearance of Uremic Solutes | Kidney clearance of uremic solutes at 1 week for each study arm | mL/min | MEAN | |
| SECONDARY | Change in Quality of Life Questionnaire Score | Change from baseline quality of life score at 1 week for each study arm | Because the plan was to administer the intervention as a single dose, the investigators determined that the KDQOL should be removed from the study design because it is an evaluation used to assess changes over time. This decision was made prior to enrollment of any participants and was not administered to any study participants; however, the measure was not removed from the registration at that time. | ||
| SECONDARY | Plasma Urea | Week 1 | mg/dL | MEAN | |
| SECONDARY | Blood Pressure | Week 1 | mmHg | MEAN | |
| SECONDARY | Weight Change | Baseline, Week 1 | kg | MEAN |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Urine Output | Metolazone | 809 | Standard Deviation 466 | mL/day | |
| Change in Urine Output | Placebo | 676 | Standard Deviation 487 | mL/day | |
| Kidney Clearance of Uremic Solutes | Metolazone | P-Cresol sulfate | 15 | Standard Deviation 11 | mL/min |
| Kidney Clearance of Uremic Solutes | Placebo | P-Cresol sulfate | 10 | Standard Deviation 8 | mL/min |
| Kidney Clearance of Uremic Solutes | Metolazone | Indoxyl sulfate | 34 | Standard Deviation 20 | mL/min |
| Kidney Clearance of Uremic Solutes | Placebo | Indoxyl sulfate | 22 | Standard Deviation 15 | mL/min |
| Kidney Clearance of Uremic Solutes | Metolazone | Hippurate | 61 | Standard Deviation 48 | mL/min |
| Kidney Clearance of Uremic Solutes | Placebo | Hippurate | 42 | Standard Deviation 29 | mL/min |
| Kidney Clearance of Uremic Solutes | Metolazone | Phenylactyl glutamine | 14 | Standard Deviation 9 | mL/min |
| Kidney Clearance of Uremic Solutes | Placebo | Phenylactyl glutamine | 9 | Standard Deviation 7 | mL/min |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period 1 (1 Week) | STARTED | Metolazone Then Placebo | 3 | |
| Treatment Period 1 (1 Week) | STARTED | Placebo Then Metolazone | 3 | |
| Treatment Period 1 (1 Week) | COMPLETED | Metolazone Then Placebo | 3 | |
| Treatment Period 1 (1 Week) | COMPLETED | Placebo Then Metolazone | 3 | |
| Treatment Period 1 (1 Week) | NOT COMPLETED | Metolazone Then Placebo | 0 | |
| Treatment Period 1 (1 Week) | NOT COMPLETED | Placebo Then Metolazone | 0 | |
| Washout Period (2 Weeks) | STARTED | Metolazone Then Placebo | 3 | |
| Washout Period (2 Weeks) | STARTED | Placebo Then Metolazone | 3 | |
| Washout Period (2 Weeks) | COMPLETED | Metolazone Then Placebo | 3 | |
| Washout Period (2 Weeks) | COMPLETED | Placebo Then Metolazone | 3 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Metolazone | 0 | 6 |
| Total, all-cause mortality | Placebo | 0 | 6 |
| Total, other adverse events | Metolazone | 0 | 6 |
| Total, other adverse events | Placebo | 0 | 6 |
| Total, serious adverse events | Metolazone | 0 | 6 |
| Total, serious adverse events | Placebo | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Metolazone vs Placebo: deaths from any cause | Trial comparisons |
| Metolazone vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04542304
GET https://conductscience.org/api/trials/v1/NCT04542304/registered